This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The recent favorable meta-analysis of tacrine for treating Alzheimer disease by Dr Qizilbash and colleagues¹ did not consider the potential influence of corporate sponsorship on the reported studies. Studies without corporate support found no clinical effect (references 1, 13, 14, 16, and 21 in the article). All but 1 (reference 24) of the manufacturer-supported studies found clinical benefit (references 15, 17-20, and 22). We could not locate 1 study (reference 23).

Corporate support took the form of authors who were employed by the manufacturer, received grants, or held stocks or stock options of the manufacturer; in-house research of methodological or statistical analysis provided by the manufacturer; or unidentified support. Four of the authors of the favorable meta-analysis are listed as having had or currently receiving support from the manufacturer of tacrine or similar agents.

Industry-supported research tends to showcase products.^2-3 This does not invalidate such studies, industry . . . [Full Text of this Article]